Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis
- 1 February 2023
- journal article
- letter
- Published by Mary Ann Liebert Inc in Thyroid®
- Vol. 33 (2), 267-269
- https://doi.org/10.1089/thy.2022.0398
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference centerJournal of Endocrinological Investigation, 2022
- Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumabActa Neurologica Belgica, 2022
- New Therapeutic Horizons for Graves’ HyperthyroidismEndocrine Reviews, 2020
- Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment ResponseJournal of Clinical Endocrinology & Metabolism, 2020
- Thyroid autoimmunity and dysfunction associated with type I interferon therapyClinical and Experimental Medicine, 2004